P549: Changing Lanes: Switching Therapies in Inflammatory Bowel Disease, An Observational Study.ECCO'21 VirtualYear: 2021
Authors: Mc Gettigan, N.(1);Leung, E.(2);Harhen, A.(2);Anderson, E.(2);McMahon, S.(2);Walshe, M.(2);Keohane, J.(2);Sengupta, S.(2);
(1)Our Lady of Lourdes Hospital- Drogheda, Gastroenterology, Galway, Ireland;(2)OLOL Drogheda, Gastroenterology, Drogheda, Ireland
P550: Short term effects of a combined lifestyle intervention in patients with Inflammatory Bowel DiseaseECCO'21 VirtualYear: 2021
Authors: Lamers, C.R.(1,2);de Roos, N.M.(2);Heerink, H.H.(3);van de Worp - Kalter, L.A.(4);Witteman, B.J.M.(1,2);
(1)Hospital Gelderse Vallei, Gastroenterology and Hepatology, Ede, The Netherlands;(2)Wageningen University & Research, Human Nutrition and Health, Wageningen, The Netherlands;(3)Hospital Gelderse Vallei, Dietetics, Ede, The Netherlands;(4)Hospital Gelderse Vallei, Physical Therapy, Ede, The Netherlands
P551: Lack of adherence to infliximab in inflammatory bowel disease patients contributes to loss of response in Crohn’s disease.ECCO'21 VirtualYear: 2021
Authors: Ferreiro Iglesias, R.(1);Gonzalez-Lopez, J.(2);Calvino-Suarez, C.(1);Mauriz-Barreiro, V.(1);Baston-Rey, I.(1);Cruz, R.(3);Dominguez-Munoz, J.E.(1);Barreiro-de Acosta, M.(1);
(1)University Hospital Santiago De Compostela CHUS, Department of Gastroenterology- IBD Unit, Santiago De Compostela, Spain;(2)University Hospital Santiago De Compostela CHUS, Department of Pharmacy, Santiago De Compostela, Spain;(3)Universidad de Santiago de Compostela, Grupo de Medicina Genómica, Santiago de Compostela, Spain
P552: Assessing adherence to objective disease monitoring and outcomes with adalimumab in a real-world IBD cohort.ECCO'21 VirtualYear: 2021
Authors: Xiao, Y.(1);AL Khoury, A.(2);Golovics, P.(3);Kohen, R.(2);Afif, W.(2);Wild, G.(2);Friedman, G.(4);Galiatsatos, P.(4);Hilzenrat, N.(4);Szilagyi, A.(4);Wyse, J.(4);Cohen, A.(4);Bitton, A.(4);Bessissow, T.(4);Lakatos, P.L.(2);
(1)McGill University, Department of Medicine- Internal Medicine, Montreal H3H1E1, Canada;(2)McGill University, Department of Medicine- Gastroenterology, Montreal H3H1E1, Canada;(3)HDF Medical Center, Division of Gastroenterology, Budapest, Hungary;(4)Jewish General Hospital, Department of Medicine- Gastroenterology, Montreal H3H1E1, Canada
P553: Factors related to steroid consumption in IBD patients: Evidence from a multicenter StudyECCO'21 VirtualYear: 2021
Authors: Barkan, R.(1); Shpoker , L.(2);Abboud, R.(2);Nafrin, S.(3);Ganon , M.(4);Ilsar , T.(4);Volf , T.(5);Markovitch , L.(6);Saban , M.(7);Kagan, I.(8);
(1)Rabin Medical Center - Beilinson Hospital, IBD Center- Division of Gastroenterology, Petah Tikva, Israel;(2)Bny Zion- Medical Center, IBD Center- Division of Gastroenterology, Haifa, Israel;(3)Hillel Yaffe Medical Center, . IBD Center- Division of Gastroenterology, - Hadera, Israel;(4)Hadassah Ein Kerem Medical Center, IBD Center- Division of Gastroenterology, Jerusalem, Israel;(5)Shamir Medical Center, IBD Center- Division of Gastroenterology, Tzrifin, Israel;(6)Rabin Medical Center - Hasharon Hospital, IBD Center- Division of Gastroenterology, Petah Tikva, Israel;(7)Gertner institute, for epidemiology and health policy research, Ramat-Gan, Israel;(8)School of Health Professions- Sackler Faculty of Medicine- Tel Aviv University, Nursing Department-, Tel Aviv, Israel
P554: Does vitamin D level correlates with disease activity in inflammatory bowel disease patients?ECCO'21 VirtualYear: 2021
Authors: SinaDr., M.(1);Pemaj, X.(1);Akshija, I.(2);Hysa, A.(1);Koçollari, A.(1);Prifti, S.(1);
(1)University Hospital Center Mother Theresa, Internal Medicine/ Gastroenterology, Tirana, Albania;(2)University Hospital Center Mother Theresa, Statistics, Tirana, Albania
P555: Outcomes of multiswitching from original infliximab to biosimilars in patients with inflammatory bowel diseaseECCO'21 VirtualYear: 2021
Authors: Nascimento, C.(1);Revés, J.(1);Morão, B.(1);Frias Gomes, C.(1);Gouveia, C.(1);Palmela, C.(1);Roque Ramos, L.(1);Fidalgo, C.(1);Cravo, M.(1);Glória, L.(1);Torres, J.(1);
(1)Hospital Beatriz Ângelo, Gastrenterology, Loures, Portugal
P556: Safety and efficacy of ustekinumab in the treatment of Crohn's Disease: A systematic review and meta-analysisECCO'21 VirtualYear: 2021
Authors: KhorshidFASGE, M.(1);Cordie, A.(2);Abd-Elsalam, S.(3);
(1)EDGE Foundation, Department of Clinical Research, Cairo, Egypt;(2)Cairo University, GI & Liver Endoscopy Unit, Cairo, Egypt;(3)Tanta University, Department of Tropical Medicine & Infectious Diseases, Tanta, Egypt
P559: Efficacy of Ustekinumab in the treatment of patients with Crohn’s disease with failure to previous conventional or biologic therapy: an observational real-life studyECCO'21 VirtualYear: 2021
Authors: Miranda, A.(1);Cuomo, A.(2);Camera, S.(2);Ciacci, C.(3);De Filippo, F.R.(3);Gravina, A.G.(1);D'Onofrio, V.(4);Melina , R.(4);Manguso, F.(5);PRIADKO, K.(1);Facchiano, A.(1);Bennato, R.(6);D'Onofrio, R.(1);Cuomo, R.(7);Mucherino, C.(8);Romano, M.(1);
(1)Università degli Studi della Campania 'L. Vanvitelli', Department of Precision Medicine and Endoscopy Unit, Napoli, Italy;(2)Umberto I Nocera Inferiore, U.O.C. of Gastroenterology, Nocera Inferiore, Italy;(3)University Hospital San Giovanni di Dio e Ruggi D'Aragona, U.O.C. of Gastroenterology, Salerno, Italy;(4)San Giuseppe Moscati Avellino Hospital, U.O.C. of Gastroenterology, Avellino, Italy;(5)A. Cardarelli Hospital, U.O.C. of Gastroenterology, Napoli, Italy;(6)A. Cardarelli Hospital, U.O.C. of Gastroenterology, Naples, Italy;(7)Sant'Anna and San Sebastiano Hospital, U.O.C of Gastroenterology, Caserta, Italy;(8)Caserta Hospital, U.O.C. of Gastroenterology, Caserta, Italy
P560: Clinical outcomes of vedolizumab maintenance treatment for Korean patients with inflammatory bowel disease who failed anti-TNF therapy: A KASID prospective multicenter cohort studyECCO'21 VirtualYear: 2021
Authors: Oh, K.(1);Kim, J.(2);Kim, N.(3);Yoon, H.(4);Lee, K.M.(5);Park, D.I.(6);Choi, C.H.(7);Lee, C.K.(8);Eun, C.S.(9);Kang, S.B.(10);Kim, E.S.(11);Kim, Y.S.(12);Jung, S.A.(13);Jung, Y.(14);Kim, T.O.(15);Park, S.J.(16);Im, J.P.(17);Seo, G.S.(18);Ye, B.D.(19);
(1)University of Ulsan College of Medicine- Asan Medical Center, Gastroenterology, Seoul, Korea- Republic Of;(2)Keimyung University School of Medicine, Internal Medicine, Daegu, Korea- Republic Of;(3)Asan Medical Center, Biostatistics and Clinical Epidemiology, Seoul, Korea- Republic Of;(4)Seoul National University Bundang Hospital, Internal Medicine, Seongnam, Korea- Republic Of;(5)St. Vincent's Hospital- College of Medicine- The Catholic University of Korea, Internal Medicine, Seoul, Korea- Republic Of;(6)Kangbuk Samsung Hospital- Sungkyunkwan University School of Medicine, Internal Medicine, Seoul, Korea- Republic Of;(7)Chung-Ang University College of Medicine, Internal Medicine, Seoul, Korea- Republic Of;(8)Kyung Hee University College of Medicine, Gastroenterology, Seoul, Korea- Republic Of;(9)Hanyang University Guri Hospital, Internal Medicine, Guri, Korea- Republic Of;(10)Daejeon St. Mary's Hospital- College of Medicine- The Catholic University of Korea, Internal Medicine, Daejeon, Korea- Republic Of;(11)Kyungpook National University- School of Medicine, Internal Medicine, Daegu, Korea- Republic Of;(12)Seoul Paik Hospital- Inje University College of Medicine, Internal Medicine, Seoul, Korea- Republic Of;(13)Ewha Womans University School of Medicine, Internal Medicine, Seoul, Korea- Republic Of;(14)Soonchunhyang University College of Medicine, Medicine, Cheonan, Korea- Republic Of;(15)Haeundae Paik Hospital- Inje University College of Medicine, Internal Medicine, Busan, Korea- Republic Of;(16)Severance Hospital- Yonsei University College of Medicine, Internal Medicine and Institute of Gastroenterology, Seoul, Korea- Republic Of;(17)Seoul National University College of Medicine, Internal Medicine and Liver Research Institute, Seoul, Korea- Republic Of;(18)Wonkwang University School of Medicine, Internal Medicine, Iksan, Korea- Republic Of;(19)University of Ulsan College of Medicine- Asan Medical Center, Gastroenterology and Inflammatory Bowel Disease Center, Seoul, Korea- Republic Of; IBD Research Group of the Korean Association for the Study of Intestinal Diseases
P563: Comparison of long-term outcomes of infliximab with adalimumab in biologic naïve patients with Crohn’s disease: a tertiary referral center 13-year experience.ECCO'21 VirtualYear: 2021
Authors: Yuksel, I.(1,2);Durak, M.B.(2);Kilic, V.(2);Kivrakoglu, F.(1,2);Kosar, K.(2);Erdogan, C.(2);Alkan, A.(3);
(1)Ankara Yildirim Beyazit University School of Medicine., Department of Gastroenterology., Ankara, Turkey;(2)Ankara City Hospital., Department of Gastroenterology, Ankara, Turkey;(3)Ankara Yildirim Beyazit University School of Medicine, Department of Biostatistics and Medical Informatics, Ankara, Turkey
P564: Validation of the IBD-Disk instrument in a Portuguese cohortECCO'21 VirtualYear: 2021
Authors: Silva Mendes, S.(1,2);Ferreira, P.(2);Antunes, P.(1);Gonçalves, M.(1);Leal, T.(1);Gonçalves, B.(1);Rebelo, A.(1);Arroja, B.(1);Caetano, A.C.(1,2);Gonçalves, R.(1);Soares, J.B.(1);
(1)Braga Hospital, Gastroenterology, Braga, Portugal;(2)University of Minho, Life and Health Sciences Research Institute ICVS- School of Medicine, Braga, Portugal
P565: Illness perception as a clinical tool to detect mood disturbances (anxiety or depression) in inflammatory bowel disease patients.ECCO'21 VirtualYear: 2021
Authors: De Castro Parga, M.L.(1,2);Pereyra, D.(1);Sanromán, L.(1);Figueira, M.(1);Hernández, V.(1);Pineda, J.(1);Martinez-Cadilla, J.(1);Pereira, S.(1);Rodriguez-Prada, J.I.(1);
(1)University Hospital Complex of Vigo, Department of Gastroenterology, Vigo, Spain;(2)Instituto de Investigación Sanitaria Galicia Sur IIS Galicia Sur., Sergas, Vigo, Spain
P566: Impact of induction therapy and clinical remission on resting energy expenditure in children with Crohn’s DiseaseECCO'21 VirtualYear: 2021
Authors: Kornitzer, G.(1);Breton, J.(2);Poinsot, P.(3);Godin, D.(4);Grzywacz, K.(1);Deslandres, C.(1);Groleau, V.(1);
(1)Sainte-Justine University Hospital Center, Department of Paediatrics - Division of Gastroenterology- Hepatology and Nutrition, Montreal, Canada;(2)Children's Hospital of Philadelphia, Division of Gastroenterology- Hepatology and Nutrition and Center for Pediatric Inflammatory Bowel Disease, Philadelphia, United States;(3)Hospices Civils de Lyon, Service de gastroentérologie- hépatologie et nutrition pédiatriques, Lyon, France;(4)Sainte-Justine University Hospital Center, Division of Gastroenterology- Hepatology and Nutrition, Montreal, Canada
P567: Pharmacist-managed immunomodulator clinic in titration and monitoring of immunosuppressants in Inflammatory Bowel DiseaseECCO'21 VirtualYear: 2021
Authors: Ng, V.(1);Lim, T.G.(1,2);Ong, W.C.(1);Wong, S.Y.A.(1);Salazar, E.(3);Chan, P.W.W.(2,3);
(1)Singapore General Hospital- Singapore, Pharmacy, Singapore, Singapore;(2)Duke-NUS Medical School, Medicine, Singapore, Singapore;(3)Singapore General Hospital- Singapore, Gastroenterology and Hepatology, Singapore, Singapore
P568: Effectiveness of ustekinumab after vedolizumab failure in patients with anti-TNF-refractory Crohn’s disease.ECCO'21 VirtualYear: 2021
Authors: Dussias, N.(1);Rizzello, F.(1);Calabrese, C.(1);Sanna Passino, A.(1);Melotti, L.(1);Scaioli, E.(1);Belluzzi, A.(1);Gionchetti, P.(1);
(1)University of Bologna, Dept. of surgical and medical sciences, Bologna, Italy